CatalystFDA/Bio

TEVA WINS BIOSIMILAR APPROVAL OF AMGEN'S XGEVA - SEEKINGALPHA

Teva wins biosimilar approval of Amgen's Xgeva, a competitive biotech catalyst.

What changed

Teva wins biosimilar approval of Amgen's Xgeva, a competitive biotech catalyst.

Why it matters

Teva wins biosimilar approval of Amgen's Xgeva, a competitive biotech catalyst. — impact context not separately stored; see What changed.

Sources